Latest filings (excl ownership)
15-12B
Securities registration termination
26 Mar 20
6-K
Current report (foreign)
18 Mar 20
6-K
Current report (foreign)
5 Mar 20
6-K
Current report (foreign)
29 Jan 20
EFFECT
Notice of effectiveness
30 Dec 19
EFFECT
Notice of effectiveness
30 Dec 19
POS AM
Prospectus update (post-effective amendment)
23 Dec 19
POS AM
Prospectus update (post-effective amendment)
23 Dec 19
25
Voluntary exchange delisting
9 Dec 19
6-K
Current report (foreign)
27 Nov 19
6-K
Motif Bio plc Announces Voluntary Delisting from the Nasdaq Capital Market
26 Nov 19
6-K
Current report (foreign)
18 Nov 19
6-K
Result of General Meeting
15 Nov 19
6-K
Current report (foreign)
12 Nov 19
6-K
Current report (foreign)
25 Oct 19
6-K
Current report (foreign)
3 Oct 19
6-K
Current report (foreign)
2 Oct 19
6-K
Current report (foreign)
30 Sep 19
6-K
Current report (foreign)
30 Sep 19
6-K
Motif Bio and Hercules Capital Amend Loan and Security Agreement
3 Sep 19
6-K
Motif Bio and Hercules Capital Amend Loan and Security Agreement
1 Aug 19
6-K
Motif Bio Confirms Meeting Date with U.S. FDA regarding Iclaprim
26 Jul 19
6-K
Current report (foreign)
26 Jul 19
6-K
Motif Bio Announces Receipt of Deficiency Notice from Nasdaq
19 Jul 19
6-K
Motif Bio Submits Meeting Request and Package to the U.S. FDA for Iclaprim
15 Jul 19
6-K
Motif Bio Announces Path Forward for Iclaprim following Receipt of FDA Meeting Minutes
6 Jun 19
6-K
Result of Annual General Meeting
31 May 19
6-K
Motif Bio plc AGM Statement
22 May 19
6-K
Motif Bio meeting with U.S. FDA held as planned
3 May 19
6-K
Motif Bio Announces Appointment of Andrew Powell to Board of Directors
26 Apr 19
20-F
2018 FY
Annual report (foreign)
15 Apr 19
6-K
Motif Bio Reports Fiscal Year 2018 Results
15 Apr 19
6-K
Current report (foreign)
26 Mar 19
6-K
Current report (foreign)
25 Mar 19
6-K
Motif Bio Granted Meeting with U.S. FDA regarding Iclaprim
20 Mar 19
6-K
Motif Bio Announces Appointment of Bruce Williams as Interim Chairman and Resignation of Richard Morgan from the Board
18 Mar 19
6-K
Motif BioSciences Enters into Amendment Agreement with Hercules Capital
19 Feb 19
6-K
Motif Bio Receives Complete Response Letter from the FDA
14 Feb 19
6-K
Current report (foreign)
25 Sep 18
6-K
Motif Bio notes statement from Amphion Innovations
21 Aug 18
Latest ownership filings
SC 13D/A
Motif Bio plc
28 Oct 19
SC 13D/A
Motif Bio plc
2 Apr 19
SC 13D/A
Motif Bio plc
15 Feb 19
SC 13G/A
Motif Bio plc
13 Feb 19
SC 13D
Motif Bio plc
11 Feb 19
SC 13G
Motif Bio plc
5 Feb 19
SC 13G
Motif Bio plc
14 Feb 18
SC 13D
Motif Bio plc
2 Feb 18
SC 13G/A
Motif Bio plc
8 Jan 18
SC 13G
Motif Bio plc
6 Sep 17
SC 13G
Motif Bio plc
6 Sep 17
SC 13G
Motif Bio plc
6 Sep 17
SC 13G/A
Beneficial ownership report (amended)
12 Jan 17
SC 13D
Motif Bio plc
29 Nov 16
SC 13G
Beneficial ownership report
28 Nov 16